// App-Quantinova.ai

89 : The association between poor prognostic factors at methotrexate initiation and disease activity and disability over one year: results from the Rheumatoid Arthritis Medication Study

Researchers

Presenter

  • James Gwinnutt

Principal Investigators

  • Kimme Hyrich

  • Mark Lunt

  • Darren Plant

  • Marie Brazil

  • Roelien Postema

  • Anne Barton

  • Suzanne Verstappen

Medical Centers

  • Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom

  • NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom

  • Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom

  • Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb, Uxbridge, UNITED KINGDOM

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • anti-CCP antibodies

Drug/Treatment

  • Methotrexate

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved